Fulgent Genetics (FLGT) Stock Price

Fulgent Genetics Price

NASDAQ·CLOSED
18.56USD-0.09 (-0.48 %)
Market closed

Over the last 11 years Fulgent Genetics grew revenue by 65.3% annually, reaching 322.67 M USD. Earnings per share have grown at 532.4% per year over the last 3 years. For Fulgent Genetics, the net margin of -18.8% is down versus 10.5% a few years ago. The consensus 12-month price target for Fulgent Genetics is 35.70 USD, about 92.3% above where the stock trades today. Of 9 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 40% above its 52-week low.

Fulgent Genetics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Fulgent Genetics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Fulgent Genetics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Fulgent Genetics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Fulgent Genetics Stock Price History
DateFulgent Genetics Price
8/14/202618.56 USD
8/13/202618.65 USD
8/12/202618.69 USD
8/10/202619.06 USD
8/7/202619.14 USD
8/6/202618.55 USD
8/5/202618.51 USD
8/4/202618.21 USD
8/3/202617.61 USD
7/31/202616.55 USD
7/30/202620.21 USD
7/29/202619.66 USD
7/27/202619.45 USD
7/23/202619.98 USD
7/22/202619.53 USD
7/21/202619.88 USD
7/20/202619.61 USD
7/17/202620.16 USD
7/16/202620.55 USD
7/15/202621.01 USD
7/14/202620.46 USD
7/13/202620.30 USD
7/10/202620.55 USD
7/9/202620.88 USD
7/8/202620.75 USD
7/7/202621.02 USD
7/6/202620.67 USD
7/2/202620.85 USD
7/1/202620.82 USD
6/30/202620.52 USD
6/29/202619.86 USD
6/26/202619.96 USD
6/25/202619.44 USD
6/24/202619.13 USD
6/23/202618.18 USD
6/22/202618.12 USD
6/18/202618.00 USD
6/17/202618.07 USD
6/16/202618.02 USD
6/15/202618.86 USD
6/12/202618.61 USD
6/11/202619.01 USD
6/10/202618.97 USD
6/9/202618.50 USD
6/8/202618.31 USD
6/5/202619.15 USD
6/4/202619.50 USD
6/3/202618.14 USD
6/2/202618.70 USD
6/1/202618.09 USD
5/29/202618.14 USD
5/28/202618.24 USD
5/27/202617.90 USD
5/26/202617.67 USD
5/22/202617.11 USD
5/21/202617.38 USD
5/20/202616.41 USD
5/19/202615.95 USD
5/18/202615.85 USD
5/15/202615.70 USD
5/14/202616.19 USD
5/13/202615.96 USD
5/12/202615.80 USD
5/11/202615.82 USD
5/8/202615.96 USD
5/7/202615.11 USD
5/6/202614.92 USD
5/5/202614.90 USD
5/4/202615.12 USD
5/1/202614.13 USD
4/30/202615.19 USD
4/29/202614.80 USD
4/28/202615.30 USD
4/27/202615.60 USD
4/24/202616.31 USD
4/23/202616.03 USD
4/22/202616.29 USD
4/21/202615.94 USD
4/20/202616.18 USD
4/17/202616.26 USD
4/16/202616.13 USD
4/15/202616.17 USD
4/14/202616.02 USD
4/13/202615.30 USD
4/10/202614.43 USD
4/9/202615.02 USD
4/8/202615.83 USD
4/7/202615.91 USD
4/6/202616.42 USD
4/2/202616.82 USD
4/1/202616.44 USD
3/31/202615.90 USD
3/30/202615.63 USD
3/27/202615.59 USD
3/26/202616.37 USD
3/25/202616.67 USD
3/24/202616.34 USD
3/23/202616.33 USD
3/20/202615.51 USD
3/19/202615.56 USD
3/18/202615.14 USD
3/17/202615.43 USD
3/16/202614.95 USD
3/13/202614.77 USD
3/12/202614.68 USD
3/11/202614.37 USD
3/10/202614.38 USD
3/9/202614.88 USD
3/6/202614.63 USD
3/5/202614.25 USD
3/4/202613.99 USD
3/3/202613.79 USD
3/2/202614.20 USD
2/27/202615.33 USD
2/26/202615.33 USD
2/25/202614.59 USD
2/24/202614.30 USD
2/23/202614.25 USD
2/20/202614.35 USD
2/19/202614.41 USD
2/18/202614.45 USD
2/17/202614.61 USD
2/13/202614.51 USD
2/12/202614.22 USD
2/11/202614.24 USD
2/10/202614.28 USD
2/9/202614.21 USD
2/6/202614.51 USD
2/5/202614.68 USD
2/4/202615.81 USD
2/3/202616.13 USD
2/2/202616.17 USD
1/30/202616.22 USD
1/29/202616.25 USD
1/28/202616.35 USD
1/27/202616.88 USD
1/26/202617.05 USD
1/23/202617.22 USD
1/22/202617.44 USD
1/21/202617.24 USD
1/20/202617.14 USD
1/16/202617.39 USD
1/15/202617.74 USD
1/14/202617.32 USD
1/13/202617.56 USD
1/12/202617.44 USD
1/9/202617.24 USD
1/8/202617.27 USD
1/7/202617.34 USD
1/6/202616.09 USD
1/5/202615.71 USD
1/2/202615.84 USD
12/31/202516.26 USD
12/30/202516.40 USD
12/29/202516.47 USD
12/26/202516.54 USD
12/24/202516.72 USD
12/23/202516.82 USD
12/22/202517.11 USD
12/19/202517.09 USD
12/18/202517.37 USD
12/17/202517.03 USD
12/16/202516.82 USD
12/15/202516.67 USD
12/12/202516.80 USD
12/11/202516.75 USD
12/10/202516.87 USD
12/9/202517.00 USD
12/8/202517.25 USD
12/5/202517.21 USD
12/4/202517.52 USD
12/3/202517.63 USD
12/2/202517.58 USD
12/1/202517.66 USD
11/28/202518.31 USD
11/26/202518.67 USD
11/25/202519.10 USD
11/24/202518.98 USD
11/21/202518.57 USD
11/20/202517.82 USD
11/19/202517.96 USD
11/18/202518.02 USD
11/17/202517.84 USD
11/14/202518.02 USD
11/13/202518.32 USD
11/12/202518.00 USD
11/11/202517.57 USD
11/10/202516.82 USD
11/7/202516.32 USD
11/6/202513.81 USD
11/5/202514.10 USD
11/4/202514.17 USD
11/3/202514.31 USD
10/31/202513.90 USD
10/30/202513.98 USD
10/29/202514.07 USD
10/28/202514.51 USD
10/27/202514.43 USD
10/24/202514.70 USD
10/23/202514.62 USD
10/22/202514.55 USD
10/21/202514.84 USD
10/20/202514.76 USD
10/17/202514.04 USD
10/16/202514.12 USD
10/15/202514.09 USD
10/14/202513.86 USD
10/13/202513.92 USD
10/10/202513.94 USD
10/9/202514.05 USD
10/8/202514.14 USD
10/7/202514.01 USD
10/6/202514.25 USD
10/3/202514.10 USD
10/2/202514.18 USD
10/1/202514.55 USD
9/30/202513.99 USD
9/29/202513.81 USD
9/26/202513.99 USD
9/25/202513.64 USD
9/24/202513.68 USD
9/23/202513.58 USD
9/22/202513.78 USD
9/19/202513.82 USD
9/18/202513.92 USD
9/17/202513.64 USD
9/16/202513.58 USD
9/15/202513.61 USD
9/12/202513.55 USD
9/11/202513.78 USD
9/10/202513.48 USD
9/9/202513.82 USD
9/8/202513.79 USD
9/5/202513.59 USD
9/4/202513.61 USD
9/3/202513.63 USD
9/2/202513.81 USD
8/29/202513.73 USD
8/28/202513.64 USD
8/27/202513.40 USD
8/26/202513.29 USD
8/25/202513.33 USD
8/22/202513.48 USD
8/21/202513.25 USD
8/20/202513.24 USD
8/19/202513.35 USD
8/18/202513.32 USD
Access this data via the Eulerpool API
Get Free API Key

Fulgent Genetics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
992.58 M USD
104.34 M USD
104.34 M USD
Jan 1, 2022
618.97 M USD
178.53 M USD
143.40 M USD
Jan 1, 2023
289.21 M USD
-195.53 M USD
-167.83 M USD
Jan 1, 2024
283.47 M USD
-73.92 M USD
-42.71 M USD
Jan 1, 2025
322.67 M USD
-91.10 M USD
-60.51 M USD
Jan 1, 2026 (e)
331.70 M USD
-1.03 M USD
-70.17 M USD
Jan 1, 2027 (e)
382.70 M USD
-1.18 M USD
-42.66 M USD
Jan 1, 2028 (e)
434.90 M USD
-1.27 M USD
-30.60 M USD

Fulgent Genetics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 18, 2026, 5:37 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e
1.009.0018.0018.0021.0032.00421.00992.00618.00289.00283.00322.00331.00382.00434.00
–800.00100.00–16.6752.381,215.63135.63-37.70-53.24-2.0813.782.8015.4113.61
13,000.0044.4461.1155.5647.6256.2578.6278.3359.2235.9937.8140.3740.3740.3740.37
130.004.0011.0010.0010.0018.00331.00777.00366.00104.00107.00130.00133.63154.22175.22
–-5.00–-3.00-5.00–290.00104.00178.00-195.00-73.00-91.00-1.00-1.00-1.00
–-55.56–-16.67-23.81–68.8810.4828.80-67.47-25.80-28.26-0.30-0.26-0.23
-4.00-8.00-5.00-2.00-4.00–214.00104.00143.00-167.00-42.00-60.00-70.00-42.00-30.00
–100.00-37.50-60.00100.00––-51.4037.50-216.78-74.8542.8616.67-40.00-28.57
30.7812.7717.8017.8118.1219.9827.0231.2030.9629.7730.6530.7830.7830.7830.78
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Fulgent Genetics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Fulgent Genetics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Fulgent Genetics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Fulgent Genetics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Fulgent Genetics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Fulgent Genetics stock margins

The Fulgent Genetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fulgent Genetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fulgent Genetics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
78.29 %
10.51 %
10.51 %
Jan 1, 2022
59.28 %
28.84 %
23.17 %
Jan 1, 2023
36.12 %
-67.61 %
-58.03 %
Jan 1, 2024
37.82 %
-26.08 %
-15.07 %
Jan 1, 2025
40.56 %
-28.23 %
-18.75 %
Jan 1, 2026 (e)
40.56 %
-0.31 %
-21.15 %
Jan 1, 2027 (e)
40.56 %
-0.31 %
-11.15 %
Jan 1, 2028 (e)
40.56 %
-0.29 %
-7.04 %

Fulgent Genetics Stock Revenue, EBIT, Earnings per Share

The Fulgent Genetics earnings per share therefore indicates how much revenue Fulgent Genetics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
31.81 USD
3.34 USD
3.34 USD
Jan 1, 2022
19.99 USD
5.77 USD
4.63 USD
Jan 1, 2023
9.71 USD
-6.57 USD
-5.64 USD
Jan 1, 2024
9.25 USD
-2.41 USD
-1.39 USD
Jan 1, 2025
10.48 USD
-2.96 USD
-1.97 USD
Jan 1, 2026 (e)
10.73 USD
-0.03 USD
-2.27 USD
Jan 1, 2027 (e)
12.38 USD
-0.04 USD
-1.38 USD
Jan 1, 2028 (e)
14.07 USD
-0.04 USD
-0.99 USD

Fulgent Genetics business model & stock analysis

Fulgent Genetics Inc. is a US company founded in 2011 by Jianxing (Justin) Liu and Ming Hsieh. The company has undergone remarkable development and is now active in the field of genomics and genetics. Fulgent Genetics' business model is based on the development and distribution of solutions for the diagnosis of genetic diseases. The company offers a variety of products and services that enable doctors, clinics, and laboratories to make effective diagnoses based on genetics. One of Fulgent Genetics' main divisions is the Clinical Diagnostics department, which offers a wide range of diagnostic products that allow for both molecular diagnoses and the creation of clinical profiles for patients. This enables doctors and clinics to quickly and accurately detect and treat specific diseases. Another important division of Fulgent Genetics is the Research department, which focuses on the discovery and development of new technologies and testing procedures. These technologies and procedures are of great interest to the scientific community and are used in research or clinical studies. Fulgent Genetics also offers a Pharmacogenomics department, which is a growing segment in the personalized medicine market. The goal here is to tailor medications to the patient's genetic makeup. Fulgent Genetics' technology allows for the analysis of a patient's current genetic makeup and recommends medications based on that. Another important area of Fulgent Genetics is the direct-to-consumer sales of tests. This is particularly significant in the field of ancestry and genealogy research. Fulgent Genetics offers a variety of tests in this area and has already achieved great success. Overall, Fulgent Genetics offers a wide range of products and services mainly focused on the diagnosis of genetic diseases. However, the company also goes beyond that and provides solutions for a wide range of customers and applications. Fulgent Genetics is based in the US and has experienced rapid growth since its founding. The company's success is also reflected in the many awards it has received. It has been recognized multiple times and has established a reputation as one of the leading biotechnology companies in the world.

Fulgent Genetics SWOT Analysis

Strengths

Fulgent Genetics Inc has several key strengths that contribute to its success and competitive advantage in the market:

  • Advanced Genetic Testing Technology: Fulgent Genetics Inc utilizes state-of-the-art genetic testing technology, allowing for accurate and efficient testing results.
  • Broad Testing Portfolio: The company offers a wide range of genetic testing services, covering various diseases, disorders, and conditions, catering to diverse customer needs.
  • Strong Industry Reputation: Fulgent Genetics Inc has built a solid reputation within the industry for delivering high-quality and reliable genetic testing services.
  • Established Customer Base: The company has a loyal customer base, including healthcare providers, insurance companies, and research institutions, fostering long-term relationships and repeat business.

Despite its strengths, Fulgent Genetics Inc faces certain weaknesses that may hinder its growth and performance in the market:

  • Dependency on Partnerships: The company relies on partnerships with other healthcare organizations and providers for customer referrals, which could limit its independent growth.
  • Regulatory Compliance: As a genetic testing provider, Fulgent Genetics Inc must comply with strict regulations and guidelines, which may be challenging and costly to maintain.
  • Limited Geographic Presence: The company's operations are currently concentrated in specific regions, potentially limiting its market reach and growth opportunities.
  • Competitive Market: Fulgent Genetics Inc operates in a highly competitive market, facing competition from both established players and emerging startups.

Fulgent Genetics Inc can leverage various opportunities to further expand its business and market reach:

  • Rising Demand for Genetic Testing: The increasing awareness and importance of genetic testing present a growing market opportunity for Fulgent Genetics Inc.
  • Expansion into New Markets: The company can explore untapped markets, both domestically and internationally, to broaden its customer base and revenue streams.
  • Strategic Partnerships and Collaborations: Forming strategic alliances with research institutions, pharmaceutical companies, and healthcare providers can provide access to new customers and enhance research capabilities.
  • Technology Advancements: Keeping up with advancements in genetic testing technology can give Fulgent Genetics Inc a competitive edge and attract more customers.

Fulgent Genetics Inc must address potential threats that could impact its business and market position:

  • Regulatory and Legal Challenges: Changes in regulations or legal requirements related to genetic testing may impose additional compliance burdens and affect the company's operations.
  • Market Saturation: The genetic testing market is becoming increasingly saturated, making it harder for Fulgent Genetics Inc to differentiate itself and attract new customers.
  • Rapid Technological Changes: Rapid advancements in genetic testing technologies may render current offerings obsolete if the company fails to adapt and stay at the forefront of innovation.
  • Reimbursement Pressures: Reduced reimbursement rates from insurance companies can impact the profitability of Fulgent Genetics Inc's testing services.

Weaknesses

Despite its strengths, Fulgent Genetics Inc faces certain weaknesses that may hinder its growth and performance in the market:

  • Dependency on Partnerships: The company relies on partnerships with other healthcare organizations and providers for customer referrals, which could limit its independent growth.
  • Regulatory Compliance: As a genetic testing provider, Fulgent Genetics Inc must comply with strict regulations and guidelines, which may be challenging and costly to maintain.
  • Limited Geographic Presence: The company's operations are currently concentrated in specific regions, potentially limiting its market reach and growth opportunities.
  • Competitive Market: Fulgent Genetics Inc operates in a highly competitive market, facing competition from both established players and emerging startups.

Fulgent Genetics Inc can leverage various opportunities to further expand its business and market reach:

  • Rising Demand for Genetic Testing: The increasing awareness and importance of genetic testing present a growing market opportunity for Fulgent Genetics Inc.
  • Expansion into New Markets: The company can explore untapped markets, both domestically and internationally, to broaden its customer base and revenue streams.
  • Strategic Partnerships and Collaborations: Forming strategic alliances with research institutions, pharmaceutical companies, and healthcare providers can provide access to new customers and enhance research capabilities.
  • Technology Advancements: Keeping up with advancements in genetic testing technology can give Fulgent Genetics Inc a competitive edge and attract more customers.

Fulgent Genetics Inc must address potential threats that could impact its business and market position:

  • Regulatory and Legal Challenges: Changes in regulations or legal requirements related to genetic testing may impose additional compliance burdens and affect the company's operations.
  • Market Saturation: The genetic testing market is becoming increasingly saturated, making it harder for Fulgent Genetics Inc to differentiate itself and attract new customers.
  • Rapid Technological Changes: Rapid advancements in genetic testing technologies may render current offerings obsolete if the company fails to adapt and stay at the forefront of innovation.
  • Reimbursement Pressures: Reduced reimbursement rates from insurance companies can impact the profitability of Fulgent Genetics Inc's testing services.

Opportunities

Fulgent Genetics Inc can leverage various opportunities to further expand its business and market reach:

  • Rising Demand for Genetic Testing: The increasing awareness and importance of genetic testing present a growing market opportunity for Fulgent Genetics Inc.
  • Expansion into New Markets: The company can explore untapped markets, both domestically and internationally, to broaden its customer base and revenue streams.
  • Strategic Partnerships and Collaborations: Forming strategic alliances with research institutions, pharmaceutical companies, and healthcare providers can provide access to new customers and enhance research capabilities.
  • Technology Advancements: Keeping up with advancements in genetic testing technology can give Fulgent Genetics Inc a competitive edge and attract more customers.

Fulgent Genetics Inc must address potential threats that could impact its business and market position:

  • Regulatory and Legal Challenges: Changes in regulations or legal requirements related to genetic testing may impose additional compliance burdens and affect the company's operations.
  • Market Saturation: The genetic testing market is becoming increasingly saturated, making it harder for Fulgent Genetics Inc to differentiate itself and attract new customers.
  • Rapid Technological Changes: Rapid advancements in genetic testing technologies may render current offerings obsolete if the company fails to adapt and stay at the forefront of innovation.
  • Reimbursement Pressures: Reduced reimbursement rates from insurance companies can impact the profitability of Fulgent Genetics Inc's testing services.

Threats

Fulgent Genetics Inc must address potential threats that could impact its business and market position:

  • Regulatory and Legal Challenges: Changes in regulations or legal requirements related to genetic testing may impose additional compliance burdens and affect the company's operations.
  • Market Saturation: The genetic testing market is becoming increasingly saturated, making it harder for Fulgent Genetics Inc to differentiate itself and attract new customers.
  • Rapid Technological Changes: Rapid advancements in genetic testing technologies may render current offerings obsolete if the company fails to adapt and stay at the forefront of innovation.
  • Reimbursement Pressures: Reduced reimbursement rates from insurance companies can impact the profitability of Fulgent Genetics Inc's testing services.

Fulgent Genetics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Fulgent Genetics Employees
Details
Date
Fulgent Genetics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Fulgent Genetics Segments

Fulgent Genetics Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Foreign
Other countries
China
Canada
People's Republic of China ("PRC")
Details
Date
United States
Foreign
Other countries
China
Canada
People's Republic of China ("PRC")
Jan 1, 2016
8.26 M USD
0.00 USD
2.98 M USD
3.24 M USD
3.80 M USD
0.00 USD
Jan 1, 2017
9.02 M USD
0.00 USD
3.00 M USD
0.00 USD
4.09 M USD
2.61 M USD
Jan 1, 2018
12.58 M USD
0.00 USD
4.68 M USD
0.00 USD
3.98 M USD
109,000.00 USD
Jan 1, 2019
25.01 M USD
0.00 USD
5.27 M USD
0.00 USD
2.25 M USD
0.00 USD
Jan 1, 2020
415.33 M USD
0.00 USD
4.65 M USD
0.00 USD
1.73 M USD
0.00 USD
Jan 1, 2021
978.98 M USD
13.61 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
603.15 M USD
15.82 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Fulgent Genetics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Fulgent Genetics historical P/E ratio, EBIT multiple, and P/S ratio

Fulgent Genetics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Fulgent Genetics shares outstanding

The number of shares of Fulgent Genetics was 30.78 M in 2025. This indicates how many shares Fulgent Genetics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
31.20 M Stocks
Jan 1, 2022
30.96 M Stocks
Jan 1, 2023
29.77 M Stocks
Jan 1, 2024
30.65 M Stocks
Jan 1, 2025
30.78 M Stocks
Jan 1, 2026 (e)
30.78 M Stocks
Jan 1, 2027 (e)
30.78 M Stocks
Jan 1, 2028 (e)
30.78 M Stocks

Current Fulgent Genetics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
77.78 % (7)
Hold
22.22 % (2)
Sell
0.00 % (0)
12M Price Target
35.70
Last Price
18.56
Currency
USD
12M Return Potential
92.35 %
LTM Return
0 %

Fulgent Genetics Analyst Rating Actions

DateFirmActionRatingReliability
5/5/2026
Piper Sandler
Piper Sandler
MaintainedNeutral51
11/11/2025
Piper Sandler
Piper Sandler
MaintainedNeutral51
8/5/2025
UBS
UBS
UpgradeNeutralBuy51
8/4/2025
Piper Sandler
Piper Sandler
MaintainedNeutral51
5/6/2025
Piper Sandler
Piper Sandler
MaintainedNeutral51
5/5/2025
Raymond James
Raymond James
MaintainedOutperform74
3/4/2025
Piper Sandler
Piper Sandler
MaintainedNeutral51
11/11/2024
Piper Sandler
Piper Sandler
MaintainedNeutral51
3/6/2024
Piper Sandler
Piper Sandler
MaintainedNeutral51
10/16/2023
Piper Sandler
Piper Sandler
MaintainedNeutral51

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Fulgent Genetics Earnings Calls

2025

Fulgent Genetics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/31/2026-0.47USD-95.88 MUSD-2026 Q2
5/1/2026-0.23USD-69.85 MUSD-2026 Q1
2/27/20260.03USD-87.09 MUSD-2025 Q4
5/3/2024-0.22USD-76.30 MUSD-2024 Q1
2/26/2024-0.31USD-68.49 MUSD-2023 Q4
8/2/20230.08USD-88.72 MUSD-2023 Q2
5/1/2023-0.18USD-78.32 MUSD-2023 Q1
2/21/2023-0.12USD-81.72 MUSD-2022 Q4
11/7/20220.05USD-92.73 MUSD-2022 Q3
8/4/20220.74USD-124.54 MUSD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the Fulgent Genetics stock

57/100
74
Environment
58
Social
39
Governance
E

Environment

20
Scope 1 - Direct Emissions576
Scope 2 - Indirect emissions from purchased energy3,953
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions4,528
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees58
Percentage of women in management—
Percentage of Asian employees29
Share of Asian management—
Percentage of Hispanic/Latino employees18
Hispano/Latino Management share—
Percentage of Black employees14
Black Management Share—
Percentage of white employees35
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Fulgent Genetics shareholder structure

% Name
28.34593%
Hsieh (Ming)
Hsieh (Ming)
4.66600%
Millennium Management LLC
Millennium Management LLC
2.82144%
Gao (Hanlin)
Gao (Hanlin)
0.76420%
Xie (Jian)
Xie (Jian)
0.74926%
Kim (Paul)
Kim (Paul)
0.27596%
Barrow Hanley Global Investors
Barrow Hanley Global Investors

Fulgent Genetics Beneficial Ownership Filings (SEC 13D/G)

Free Float
59.9%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
12.00%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
11.50%
10
10
SEC ↗
7.57%
Barclays PLC
Barclays PLC
SEC ↗
5.90%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
5.42%
Ramya Rao
Ramya Rao
SEC ↗
4.92%
Xi Long USA, Inc.
Xi Long USA, Inc.
SEC ↗
4.70%
Millennium Management LLC
Millennium Management LLC
SEC ↗
3.00%
Integrated Core Strategies (US) LLC
Integrated Core Strategies (US) LLC
SEC ↗

Fulgent Genetics Executives and Management Board

8 members · avg. age 63 · 38 % women

MH

Mr. Ming Hsieh (69)

Chairman of the Board, Chief Executive Officer · since 2016

6.13 M USD

Management

JX

Mr. Jian Xie (58)

President, Chief Operating Officer

2.38 M USD
PK

Mr. Paul Kim (57)

Chief Financial Officer

2.35 M USD
HG

Dr. Hanlin Gao (58)

Chief Scientific Officer, Laboratory Director

1.98 M USD
MS

Ms. Melanie Solomon

Investor Relations · since 2022

–

Board of Directors

RG

Ms. Regina Groves (66)

Independent Director

273,004.00 USD
LM

Ms. Linda Marsh (75)

Independent Director

270,500.00 USD
MN

Dr. Michael Nohaile (56)

Independent Director

268,500.00 USD

Fulgent Genetics Supply Chain

Fulgent Genetics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#Nameβ 1YTrend
1
Illumina
Supplier·Life Sciences Tools & Services·US
0.22
0.44
0.65
0.66
0.77
0.65
0.46
#Nameβ 1YTrend
1
PRA Health Sciences, Inc.
Supplier·Customer·US
0.36
0.33
0.25
-0.87
-0.86
—
—
2
Xilong Scientific A
Supplier·Customer·Chemicals·CN
-0.15
-0.51
0.61
-0.27
-0.63
-0.40
—

Frequently asked questions about Fulgent Genetics

The business model of Fulgent Genetics Inc focuses on providing comprehensive genetic testing solutions. The company leverages its proprietary technology platform to offer a wide range of genetic tests, empowering healthcare professionals and patients with accurate and actionable information regarding inherited diseases, cancer predisposition, and other genetic conditions. Fulgent Genetics Inc's business model revolves around offering high-quality testing services and genetic analysis for individuals, healthcare providers, researchers, and pharmaceutical companies. By combining advanced technology and expertise in genetics, Fulgent Genetics Inc aims to support personalized medicine and improve patient outcomes through precise diagnostics and genetic insight.

Fulgent Genetics Inc is primarily active in the healthcare and biotechnology industries.

The main competitors of Fulgent Genetics Inc in the market include companies like Invitae Corporation, Myriad Genetics Inc, and Genomic Health Inc.

Fulgent Genetics Inc is a leading genetic testing company headquartered in California, United States. Established in 2011, Fulgent Genetics has rapidly emerged as a trusted provider of comprehensive genetic testing solutions. The company specializes in Next Generation Sequencing (NGS) and offers a wide range of genetic tests for various applications, including cancer screening, carrier screening, and hereditary diseases. Fulgent Genetics is committed to leveraging advanced technology and bioinformatics to deliver accurate and actionable results. With its innovative approach and dedication to quality, Fulgent Genetics has become a recognized name in the field of genetic testing, serving healthcare professionals, researchers, and individuals worldwide.

Fulgent Genetics Inc has achieved several significant milestones. The company successfully developed a proprietary technology platform, called Next Generation Sequencing (NGS), which has revolutionized genetic testing. Fulgent Genetics Inc has also formed strategic partnerships with leading healthcare providers and institutions, expanding its reach and impact within the industry. The company has received numerous accreditations and certifications, highlighting its commitment to ensuring the highest quality standards in genetic testing services. Additionally, Fulgent Genetics Inc has experienced remarkable financial growth, with increasing revenue and consistent profitability, making it a leading player in the field of genetic testing.

Fulgent Genetics Inc is primarily present in several countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered and operates its main operations. Fulgent Genetics Inc also extends its presence to international markets, including countries in Europe, such as Germany, France, and the United Kingdom. Additionally, the company has expanded its reach in Asia, with a presence in countries like China and Japan. Fulgent Genetics Inc's global presence allows it to serve a diverse customer base and tap into various market opportunities.

Fulgent Genetics Inc represents values of innovation, integrity, and excellence in the field of genetic testing and diagnostics. The company is committed to providing accurate and reliable results to healthcare providers and patients, helping to improve patient outcomes and personalized medicine. Fulgent Genetics' corporate philosophy revolves around staying at the forefront of genetic technology advancements, continuously expanding its test menu, and maintaining a strong focus on customer satisfaction. With its state-of-the-art laboratories and a team of highly trained professionals, Fulgent Genetics Inc remains dedicated to delivering high-quality genetic testing solutions.

Analysts currently set an average price target of 34.34 USD for the Fulgent Genetics stock (median: 35.70 USD), implying +85.0 % versus the latest price. The consensus is based on 9 analyst ratings.

Fulgent Genetics Analyst Price Targets 2026

9 analysts currently rate the Fulgent Genetics stock: 7 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Fulgent Genetics to generate revenue of 331.70 M USD and earnings per share of -2.28 USD.

Fulgent Genetics Analyst Price Targets 2026

Converted at the current exchange rate, the Fulgent Genetics share trades at 16.02 EUR (18.56 USD).

The Fulgent Genetics share (FLGT) is listed on 4 stock exchanges, including: NASDAQ (FLGT), Frankfurt (7F0.F), München (7F0.MU), Düsseldorf (7F0.DU).

The company Fulgent Genetics Inc is a leading provider of genetic testing services and solutions. Founded in 2011, the company specializes in the development and commercialization of advanced genetic tests and procedures to improve diagnostic and research applications in medicine, life sciences, and agriculture. Fulgent Genetics' business model is based on developing innovative genetic tests and procedures based on the latest scientific knowledge and technologies. The company offers a wide range of genetic tests and procedures that allow for accurate diagnosis of genetic diseases. Their products include prenatal genetic tests for early detection of congenital anomalies, cancer genetics tests for identifying cancer-causing gene mutations, tests for rare genetic diseases, carrier tests for detecting carriers of genetic diseases, and pharmacogenomics tests for personalized medicine. Fulgent Genetics operates two business segments: diagnostics and research. Under the diagnostics segment, the company provides genetic tests for clinical diagnosis of genetic diseases in medicine. These tests are used by patients, physicians, and healthcare organizations to identify genetic risks, diagnose diseases, and determine treatment options. Under the research segment, the company offers products for research institutions and companies working on researching genetic connections for the development of new treatment methods. The company has developed a user-friendly online portal that allows customers to easily access its services. The portal provides an intuitive interface for ordering genetic tests and monitoring the progress of test results. Fulgent Genetics also offers customization services for specific tests to meet the different needs of customers. Fulgent Genetics aims to become a preferred partner for healthcare organizations, research institutions, and companies for genetic diagnostic and research services. The company strives to continually improve its research and development capabilities and explore growth opportunities through expansion strategies and new partnerships. In summary, Fulgent Genetics offers a wide range of innovative and user-friendly genetic tests and procedures that enable accurate diagnosis of genetic diseases. The company aims to become a preferred partner for healthcare organizations, research institutions, and companies for genetic diagnostic and research services by continually improving its research and development capabilities and exploring growth opportunities through expansion strategies and new partnerships.

The expected revenue of Fulgent Genetics is 331.70 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Fulgent Genetics is -70.17 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Fulgent Genetics is currently -8.14. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fulgent Genetics stock.

The price-to-sales ratio (P/S) of Fulgent Genetics is currently 1.72. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fulgent Genetics stock.

The Eulerpool Quality Score for Fulgent Genetics is 2/10.

The ISIN of Fulgent Genetics is US3596641098. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Fulgent Genetics is A2AS4N. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Fulgent Genetics is FLGT. The ticker symbol is used to trade Fulgent Genetics shares on the stock exchange.

Fulgent Genetics paid dividends every year for the past 0 years.

Fulgent Genetics is assigned to the 'Health' sector.

The dividends of Fulgent Genetics are distributed in USD.

All fundamentals and in-depth analysis of Fulgent Genetics

Our stock analysis for Fulgent Genetics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fulgent Genetics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Fulgent Genetics Stock
Fulgent Genetics Revenue→
Fulgent Genetics Stock
Fulgent Genetics Net Income→
Fulgent Genetics Stock
Fulgent Genetics P/E→
Fulgent Genetics Stock
Fulgent Genetics P/S→
Fulgent Genetics Stock
Fulgent Genetics EBIT→
Fulgent Genetics Stock
Fulgent Genetics Dividend→
Fulgent Genetics Stock
Fulgent Genetics Directors Dealings→
Fulgent Genetics Stock
Fulgent Genetics Stocks→
Fulgent Genetics Stock
Fulgent Genetics Market capitalization→
Fulgent Genetics Stock
Fulgent Genetics Debt→
Fulgent Genetics Stock
Fulgent Genetics Liabilities→
Fulgent Genetics Stock
Fulgent Genetics Equity→
Fulgent Genetics Stock
Fulgent Genetics AAQS→
Fulgent Genetics Stock
Fulgent Genetics Employees→
Fulgent Genetics Stock
Fulgent Genetics ROE→
Fulgent Genetics Stock
Fulgent Genetics ROA→
Fulgent Genetics Stock
Fulgent Genetics ROCE→
Fulgent Genetics Stock
Fulgent Genetics News→
Fulgent Genetics Stock
Fulgent Genetics Analyst Price Targets→

Health Stocks

Fullhope Biomedical CoFulcrum TherapeuticsFunPep CoFukuda Denshi CoFuse MedicalFujian Cosunter Pharmaceutical CoFusen Pharmaceutical CoFuji Pharma CoFusion AntibodiesFuan Pharmaceutical Group CoFuso Pharmaceutical IndustriesFrontier BiotechnologiesAll Stocks A–Z →